<DOC>
	<DOCNO>NCT02034279</DOCNO>
	<brief_summary>The aim study evaluate whether albumin administration improve short-term survival patient advance cirrhosis bacterial infection Spontaneous Bacterial Peritonitis ( SBP ) .</brief_summary>
	<brief_title>The INFECIR-2 Albumin Prevention Study</brief_title>
	<detailed_description>The aim study evaluate IV albumin administration improve short-term survival patient advanced cirrhosis ( serum creatinine ≥ 1.2 mg/dl , serum sodium ≤ 130 mEq/l -milliequivalents per liter- and/or serum bilirubin ≥4 mg/dl ) bacterial infection spontaneous bacterial peritonitis ( urinary infection , pneumonia , spontaneous secondary bacteremia , skin/soft tissue infection , acute cholangitis suspect bacterial infection ) . Primary goal study : • Effect albumin administration hospital survival Secondary goal study : - Effect albumin administration 28-day 90-day survival . - Effect albumin administration incidence renal dysfunction , AKI , type-1 2 Hepatorenal Syndrome ( HRS ) hospitalization . - Effect albumin circulatory function estimate change plasma level renin noradrenaline serum level lactate among infection diagnosis , day 3 infection resolution . - Effect albumin serum level interleukin-6 ( IL-6 ) , tumor necrosis factor alpha ( TNF-alpha ) nitric oxide ( NOX ) plasma level von Willebrand factor ( vWF : Ag ) diagnosis resolution infection . - Effect albumin blood leukocyte count serum C-reactive protein level ( CRP ) infection . - Effect albumin development individual organ failure ( renal , liver , cerebral , circulatory , coagulation respiratory ) , acute-on-chronic liver failure ( ACLF type 1 , 2 3 accord Canonic Study ) , CLIF-SOFA score , CLIF-Consortium score , Child-Pugh score MELD score hospitalization . - Evaluation predictive factor HRS ACLF development non-SBP infection . - Samples ( blood , plasma , serum urine ) obtain stored genomic , proteomic standard biochemical investigation future ancillary study relate aim study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Cirrhotic patient age ≥18 year Diagnosis urinary infection , pneumonia , spontaneous secondary bacteremia , skin/soft tissue infection , acute cholangitis suspect bacterial infection hospital admission hospitalization Patients uncomplicated urinary infection suspect bacterial infection require presence sign systemic inflammation : least 1 diagnostic criterion systemic inflammatory response syndrome ( SIRS ) serum CRP level ≥1 mg/dl ( 10 mg/L ) . This criterion require rest infection Analytical data renal and/or liver dysfunction ( serum creatinine ≥ 1.2 mg/dl , serum sodium ≤ 130 mEq/l , serum bilirubin ≥4 mg/dl ) . Patients pneumonia document bacteremia ( positive blood culture ) require presence least 1 analytical criterion include study . Patients urinary infection , skin/soft tissue infection , acute cholangitis suspect bacterial infection require 2 criterion inclusion &gt; 72h infection diagnosis Pregnancy Acute subacute liver failure without underlie cirrhosis Septic shock Severe acute respiratory distress syndrome ( Pa02/Fi02 ≤ 100 ) Active recent variceal bleed unless control &gt; 48h Ongoing type1 HRS ( past IAC criterion : serum creatinine ≥ 2.5 mg/dl ) Type3 ACLF ( define accord Canonic Study criterion ) Hemodialysis renal replacement therapy Evidence current malignancy ( except hepatocellular carcinoma within Milan criterion nonmelanocytic skin cancer ) Moderate severe chronic heart ( NYHA class II , III IV ) pulmonary disease ( GOLD IV ) Severe psychiatric disorder Previous liver transplantation HIV infection ( except patient antiretroviral therapy undetectable viral load , CD4 &gt; 200/mm3 history opportunistic infection diagnostic AIDS ) Contraindications albumin ( allergy , sign pulmonary edema ) Albumin administration ( ≥ 80g ) last 2 day Spontaneous bacterial peritonitis coinfection Use investigational drug within 90 day prior randomization Refusal participate Patients provide prior informed consent document evidence patient legal surrogate decision maker appear unlikely patient regain consciousness sufficient ability provide delay informed consent Physician team commit intensive care need .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>cirrhosis</keyword>
</DOC>